New molecular concepts and targets in acute myeloid leukemia
- 1 March 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 15 (2) , 82-87
Abstract
Most patients with acute myeloid leukemia treated with chemotherapy relapse. It is increasingly recognized that the cause of chemoresistance and relapse resides within the leukemia stem cell population. Successful eradication of leukemia stem cells would require a comprehensive profile of both the acquired molecular lesions and intrinsic features of leukemia stem cells. This review describes recent work identifying molecular markers that may lead to development of novel therapeutics, ultimately aiming to eradicate leukemia stem cells in acute myeloid leukemia. In recent years, novel specific cell surface antigens have allowed identification of leukemia stem cells and permitted their distinction from normal hematopoietic stem cells. Novel concepts of leukemia stem cells and niche interaction have elucidated the mechanisms that control leukemia stem cell survival and chemoresistance. Recent detection of genetic aberrations affecting regulators of HOX gene expression and chromatin modifying enzymes, such as CDX2 and hDOT1L, respectively, elucidates new key players in stem cell self-renewal and leukemic transformation. The discovery of novel markers and survival pathways for leukemia stem cells has increased our potential to specifically target and eliminate the leukemic stem cell compartment, which is likely to improve clinical outcomes in acute myeloid leukemia.Keywords
This publication has 48 references indexed in Scilit:
- Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemiaCancer Cell, 2006
- Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9Nature, 2006
- Leukaemia stem cells and the evolution of cancer-stem-cell researchNature Reviews Cancer, 2005
- Complexity of the human acute myeloid leukemia stem cell compartment: Implications for therapyTransplantation and Cellular Therapy, 2005
- MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitorsCancer Cell, 2004
- MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemiaLeukemia, 2004
- Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitorsGenes & Development, 2003
- High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcomeLeukemia, 2003
- The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38− leukemic progenitorsLeukemia, 1999
- Most Acute Myeloid Leukemia Progenitor Cells With Long-Term Proliferative Ability In Vitro and In Vivo Have the Phenotype CD34+/CD71−/HLA-DR−Blood, 1998